Compare Lemonade Inc (LMND) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Lemonade Inc trades at $46.46 (market cap $3.63B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.65 (market cap $2.27B). The key difference: Lemonade Inc is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals.
| LMND | SLS | |
|---|---|---|
Market Cap | $3.63B | $2.27B |
Volume | 1,544,794 | 4,179,659 |
Sector | Financials | Health |
52-Week High | $96.57 | $15.46 |
52-Week Low | $43.91 | $1.39 |
Typical Hold Time | 27 Days | — |
Enterprise Value | $3.49B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $46.91, up 0.17% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $738 million, and net losses narrowing to -$166 million. Recent news highlights expansion into new states and AI-driven efficiency gains, with management targeting EBITDA profitability by late 2026.
The outlook is mixed: growth and margin improvement offer upside, but persistent losses and high valuation multiples pose risks. Analysts are divided with a consensus price target of $67, suggesting potential upside if profitability targets are met. Key risks include execution on profitability and competitive pressures in the insurtech space.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
